These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 16820380

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. The assessment of ankylosing spondylitis in clinical practice.
    Sengupta R, Stone MA.
    Nat Clin Pract Rheumatol; 2007 Sep; 3(9):496-503. PubMed ID: 17762848
    [Abstract] [Full Text] [Related]

  • 24. Do TNF-blockers reduce or induce uveitis?
    Cobo-Ibáñez T, del Carmen Ordóñez M, Muñoz-Fernández S, Madero-Prado R, Martín-Mola E.
    Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice.
    Elewaut D, Matucci-Cerinic M.
    Rheumatology (Oxford); 2009 Sep; 48(9):1029-35. PubMed ID: 19561158
    [Abstract] [Full Text] [Related]

  • 28. [Recommendations for starting anti TNF-alpha in patients with ankylosing spondylitis].
    Olivieri I, Salvarani C, Cantini F, Punzi L, Matucci Cerinic M.
    Reumatismo; 2003 Sep; 55(4):220-3. PubMed ID: 14872220
    [No Abstract] [Full Text] [Related]

  • 29. Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies.
    Kievit W, Fransen J, Adang EM, Kuper HH, Jansen TL, De Gendt CM, De Rooij DJ, Brus HL, van de Laar MA, Van Riel PC.
    Ann Rheum Dis; 2009 Jun; 68(6):844-9. PubMed ID: 18625616
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Comparison of recommendations for the use of anti-tumour necrosis factor therapy in ankylosing spondylitis in 23 countries worldwide.
    van den Berg R, Stanislawska-Biernat E, van der Heijde DM.
    Rheumatology (Oxford); 2011 Dec; 50(12):2270-7. PubMed ID: 22019804
    [Abstract] [Full Text] [Related]

  • 33. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
    Coates LC, McGonagle DG, Bennett AN, Emery P, Marzo-Ortega H.
    Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
    [No Abstract] [Full Text] [Related]

  • 34. Relapsing cutaneous leishmaniasis in a patient with ankylosing spondylitis treated with infliximab.
    Mueller MC, Fleischmann E, Grunke M, Schewe S, Bogner JR, Löscher T.
    Am J Trop Med Hyg; 2009 Jul; 81(1):52-4. PubMed ID: 19556566
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Drug insight: Anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation.
    Skomsvoll JF, Wallenius M, Koksvik HS, Rødevand E, Salvesen KA, Spigset O, Kvien TK.
    Nat Clin Pract Rheumatol; 2007 Mar; 3(3):156-64. PubMed ID: 17334338
    [Abstract] [Full Text] [Related]

  • 37. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.
    Song IH, Rudwaleit M, Listing J, Sieper J.
    Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168
    [Abstract] [Full Text] [Related]

  • 38. C-reactive protein predicts tumor necrosis factor-alpha blocker retention rate in axial ankylosing spondylitis.
    Luc M, Gossec L, Ruyssen-Witrand A, Salliot C, Duclos M, Guignard S, Dougados M.
    J Rheumatol; 2007 Oct; 34(10):2078-81. PubMed ID: 17722225
    [Abstract] [Full Text] [Related]

  • 39. [Treatment guidelines for ankylosing spondylitis and its effect on Mexican rheumatology].
    Burgos-Vargas R, Abud-Mendoza C, Díaz-Jouanen E, Garza-Elizondo MA, Medrano-Ramírez G, Orozco-Alcalá J, Pacheco-Tena C, Pineda-Villaseñor C, Carlos-Pozos J, Ramos-Niembro F, Robles-San Román M, Santana-Sahagún E.
    Gac Med Mex; 2009 Oct; 145(1):41-9. PubMed ID: 19256410
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.